Thank you, Mr. Chair.
In reference to our previous conversation, I want to make note that you indicated that we can't rely on these studies and things unless they're significant. I think it's important to note that the one in the U.S. was done by the FDA, and a significant portion of the U.S. military participated. The other two were done by the British House of Commons and by the Australian Department of Veterans' Affairs. These would be very credible studies that I think would be important for Canada to take a look at in discussing mefloquine.
I have three very quick questions for very short answers.
In 1999, Brigadier-General Claude Auger, surgeon general and commander of the Canadian Forces Medical Group of the Department of National Defence, was asked some questions by the Standing Committee on Public Accounts. He was answering the question on what we have done since Somalia to better control distribution of unlicensed drugs, and he said, “We are also in the process of developing an adverse effect monitoring and reporting database”.
Are you aware of whether that database exists? Is that something this committee could have some feedback from or access to?